Michael Rowbotham
Director/Board Member bij The University of California, San Francisco
Profiel
Michael Rowbotham has been Chief Medical Officer of Adamas Pharmaceuticals, Inc. since June, 2006.
He is Professor of Neurology and a Director of the Pain Research Center and the Clinical Research, Ernest Gallo Clinic and Research Center at the University of California, San Francisco (UCSF).
Dr. Rowbotham received his BA degree in Biology from the University of California, San Diego and an MD from the University of California, San Francisco.
Actieve functies van Michael Rowbotham
| Bedrijven | Functie | Begin |
|---|---|---|
| The University of California, San Francisco | Director/Board Member | - |
Eerdere bekende functies van Michael Rowbotham
| Bedrijven | Functie | Einde |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Michael Rowbotham
| University of California San Diego | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
